Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
Jugdutt
Bodh I
BI
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000494:pharmacology; D007783:Lactones / Q000009:adverse effects / Q000494:pharmacology; D009203:Myocardial Infarction / Q000473:pathology / Q000503:physiopathology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects / Q000502:physiology; D011720:Pyrazoles / Q000009:adverse effects / Q000494:pharmacology; D012307:Risk Factors; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology; D013450:Sulfones / Q000009:adverse effects / Q000494:pharmacology; D020257:Ventricular Remodeling / Q000187:drug effects / Q000502:physiology*; D000096926:Benzenesulfonamides
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D007783:Lactones; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides